Company Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.
In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer.
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1887 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 34,100 |
| CEO | Dr. Christopher S. Boerner Ph.D. |
Contact Details
Address: Route 206 And Province Line Road Princeton, New Jersey 08543 United States | |
| Phone | (609) 252-4621 |
| Website | bms.com |
Stock Details
| Ticker Symbol | BMY |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000014272 |
| CUSIP Number | 110122108 |
| ISIN Number | US1101221083 |
| Employer ID | 22-0790350 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer and Chairman |
| David V. Elkins | Executive Vice President and Chief Financial Officer |
| Sandra Leung Esq. | Executive Vice President and General Counsel |
| Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer and Head of Development |
| Greg Meyers | Executive Vice President and Chief Digital and Technology Officer |
| Timothy Power | Vice President and Head of Investor Relations |
| Kimberly M. Jablonski | Chief Compliance and Ethics Officer |
| Ahn Amanda Poole | Executive Vice President and Chief Human Resources Officer |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs |
| Adam Lenkowsky | Executive Vice President, Chief Commercialization Officer and Head of U.S. Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | ARS | Filing |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 18, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 18, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 424B5 | Filing |
| Feb 15, 2024 | 8-K | Current Report |
| Feb 15, 2024 | FWP | Free Writing Prospectus |